What is Blinding?
Blinding (sometimes spelt “bliding” in searches, and also called masking) is a method used in experimental research that keeps one or more parties — participants, researchers, data collectors or analysts — unaware of which intervention each participant receives. The aim is simple: when people do not know who is getting the active treatment and who is getting a placebo, they cannot let their expectations distort the results. This makes blinding one of the most effective ways to reduce bias in a clinical trial.
Blinding is most closely associated with the randomised controlled trial (RCT), the gold standard of clinical research. In a typical drug trial, patients are randomly allocated to either a treatment group or a control group, and they are not told which group they are in.
“Blinding (sometimes called masking) refers to keeping trial participants, investigators or outcome assessors unaware of the assigned intervention, so that they are not influenced by that knowledge.” — Adapted from the CONSORT 2010 Statement (Schulz et al., BMJ)
Two terms are essential to understanding blinding:
- A placebo is a dummy treatment — for example, a sugar pill — that looks identical to the active treatment but contains no active ingredient.
- A control group is the group that does not receive the active treatment (often receiving the placebo instead). It provides the baseline against which the treatment group is compared. In a well-designed double-blind test, the placebo recipients are the control group, but they do not know it.
Frequently, the identity of the treatment is concealed too. Patients might know they are taking part in an osteoporosis trial, for instance, but have no information about the specific brand or drug being tested.
Why is Blinding Important in Research?
Blinding matters because both participants and researchers carry expectations into a study. A researcher who expects a particular result may — consciously or not — interpret ambiguous data in a way that favours their preferred hypothesis. A participant who knows they are receiving an active drug may report feeling better simply because they expect to. This is the well-documented placebo effect, and it is precisely what blinding is designed to neutralise.
The risk of bias is greatest with subjective outcomes such as pain, mood, fatigue or quality of life, where there is no purely objective measurement and human judgement plays a large role.
Empirical evidence supports this. A landmark methodological study found that trials lacking adequate blinding tended to exaggerate treatment effects compared with properly blinded trials.
“On average, trials that were not double-blinded yielded larger estimates of treatment effects than trials in which authors reported double-blinding (by 17%).” — Schulz, Chalmers, Hayes & Altman, JAMA, 1995
The main benefits of blinding in research are:
- Improves internal validity — differences between groups are more likely to be caused by the treatment, not by expectation.
- Ensures unbiased outcome assessment — assessors cannot, even unintentionally, score the treatment group more favourably.
- Increases reliability and credibility, strengthening the study’s reliability and validity.
- Reduces differential behaviour — participants who don’t know their group are less likely to drop out differently or seek extra treatment.
How Blinding Works in Practice
In a practical trial, blinding is achieved through a few standard mechanisms. The active treatment and the placebo are manufactured to look, taste and feel identical, so that no one can distinguish them by appearance. Each unit is then given a random code by an independent party, and an allocation schedule linking codes to groups is locked away and held only by someone who is not involved in delivering or assessing the treatment. This is what allows a study to remain blind right up to the point of analysis.
Researchers also build in checks for “unblinding”. If participants can guess their allocation — perhaps because of an obvious side effect — the protection that blinding offers is weakened, so well-run trials report how successful the blinding actually was. Where a participant’s safety requires it, the code can be broken early for that individual, a step known as emergency unblinding. Each of these measures protects the same goal: ensuring that any measured difference between groups reflects the treatment itself, not knowledge of who received it.
Different Types of Blinding
Blinding is usually classified by how many of the parties involved are kept unaware. There are three common types:
- Single-blind trial
- Double-blind trial
- Triple-blind trial
1. Single-Blind Trial
In a single-blind trial, only one party — usually the participant — is kept unaware of the group allocation. The participants do not know whether they are receiving the active treatment or the placebo, but the researchers do. This guards against the placebo effect and participant expectation, but it does not protect against researcher bias.
2. Double-Blind Trial
In a double-blind trial, neither the participants nor the researchers interacting with them know who is in which group. The treatments are typically coded and randomly numbered so that allocation can only be revealed after data collection is complete. This is the most widely used design in drug trials because it controls for bias on both sides.
3. Triple-Blind Trial
In a triple-blind trial, three parties are kept unaware: the participant, the researcher administering the treatment, and the person collecting or analysing the data. Concealing the allocation from the data analysts means that even the statistical analysis cannot be skewed by knowing which group is which.
- The participant
- The researcher (treatment administrator)
- The data collector / analyst
Someone must, of course, hold the code — otherwise the trial could never be unblinded and analysed. In a triple-blind trial this is typically the principal investigator or an independent data-monitoring committee, who is not involved in day-to-day assessment.
Single vs Double vs Triple-Blind: Comparison
The table below summarises who is blinded in each design and the main bias each one controls.
| Type | Participant blinded? | Researcher blinded? | Data collector/analyst blinded? | Main bias controlled |
|---|---|---|---|---|
| Single-blind | Yes | No | No | Participant expectation / placebo effect |
| Double-blind | Yes | Yes | No (usually) | Participant expectation + researcher / assessor bias |
| Triple-blind | Yes | Yes | Yes | Participant + researcher + analysis / interpretation bias |
Designing a blinded study or analysing trial data?
ResearchProspect to the rescue!
Our statisticians can help you design a robust blinded trial and run the numbers — explore our statistical analysis service.
When is Blinding Not Possible?
Although single, double and triple blinding are powerful, they are not always feasible or ethical. In some studies the nature of the intervention makes concealment impossible, and forcing a blind design could compromise safety or honesty.
Common situations where blinding is difficult or impossible include:
- Surgical or physical interventions — you cannot easily disguise an operation or a course of physiotherapy, since both the clinician and the patient know what was done.
- Lifestyle and behavioural studies — participants told to exercise, change diet or stop smoking obviously know their assigned behaviour.
- Treatments with obvious side effects — a drug with a distinctive taste or noticeable effects can “unblind” participants.
- Ethical limits — using a placebo may be unethical where an effective standard treatment already exists.
There are also practical costs to consider. Blinding can add expense and complexity: identical placebos must be manufactured, codes managed, and procedures put in place for emergency unblinding. In some cases an over-engineered blind design can even discourage participation. Researchers therefore weigh the risk of bias against feasibility, and document their reasoning so that readers can judge how much the results might be affected.
When full blinding is impossible, researchers can still reduce bias by blinding the outcome assessors and data analysts even if participants cannot be blinded — sometimes called assessor-blind or PROBE (Prospective Randomised Open Blinded End-point) designs. Choosing the right design and, later, the appropriate statistical test is essential to keeping conclusions trustworthy.
